Cessatech A/S Logo

Cessatech A/S

Develops a non-invasive nasal spray for acute pain relief in children during medical procedures.

CESSA | SPGR

Overview

Corporate Details

ISIN(s):
DK0061411964
LEI:
549300WO5SKVXWPOXR16
Country:
Denmark
Address:
Kanonbådsvej 2, 1437 København K
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cessatech A/S is a pharmaceutical company specializing in the development and commercialization of evidence-based medicines for children. The company focuses on addressing unmet needs in pediatric care, particularly the treatment of acute pain. Its lead asset, CT001, is a non-invasive analgesic nasal spray for children aged 1-17 undergoing painful medical procedures. This product is designed as an alternative to traditional pain management solutions, such as intravenous injections, which can be distressing for young patients. Originating as a spinout project from Rigshospitalet, Cessatech's business model centers on developing drugs with a potentially shortened time-to-market. The management team has a proven track record in drug development, paediatric research, and global product launches.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cessatech A/S filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cessatech A/S

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cessatech A/S via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Crinetics Pharmaceuticals, Inc. Logo
Develops novel therapeutics for rare endocrine diseases and related tumors.
United States of America
CRNX
CRISPR Therapeutics AG Logo
Develops transformative CRISPR gene-based medicines for diseases like sickle cell.
United States of America
CRSP
Crossject Logo
Develops needle-free auto-injectors for rapid drug delivery in medical emergencies.
France
ALCJ
CTC BIO, INC. Logo
Develops pharmaceuticals and feed additives for human and animal health using fermentation tech.
South Korea
060590
Cue Biopharma, Inc. Logo
Develops injectable biologics to selectively activate T cells for oncology & autoimmune disease.
United States of America
CUE
Cullinan Therapeutics, Inc. Logo
Developing differentiated immune-modulating therapies for cancer and autoimmune diseases.
United States of America
CGEM
CUMBERLAND PHARMACEUTICALS INC Logo
Acquires and commercializes branded medicines for acute care, gastroenterology, and oncology.
United States of America
CPIX
Cuorips Inc. Logo
Develops iPS cell therapies, like a cardiomyocyte sheet for severe heart failure.
Japan
4894
Cuprina Holdings (Cayman) LTD Logo
Biomedical firm specializing in Maggot Debridement Therapy for wound care in Singapore & Hong Kong.
United States of America
CUPR
curacle co., ltd. Logo
Developing drugs for intractable diseases like diabetes caused by vascular damage and aging.
South Korea
365270

Talk to a Data Expert

Have a question? We'll get back to you promptly.